Wei Yirui, He Weifeng, Xie Dawei, Yang Pushen, Wang Hao, Lu Jun, Liang Xiaolong, Wang Jianwen
Department of Urology, Beijing Chaoyang Hospital, Capital Medical University, 8 Gongtinanlu, Chaoyang District, Beijing, 100020, China.
Department of Pathology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, 100020, China.
Sci Rep. 2025 Apr 12;15(1):12594. doi: 10.1038/s41598-025-96315-w.
The objective of this study is to evaluate the clinical presentations, treatment strategies, and prognostic factors for prostate diffuse large B-cell lymphoma (DLBCL), aiming to improve patient management and outcomes. We conducted a retrospective analysis of four prostate DLBCL cases treated at Beijing Chaoyang Hospital between 2014 and 2024, integrating these findings with data from the surveillance, epidemiology, and end results (SEER) dataset (2000-2021) to provide a broader context. All four patients underwent thorough diagnostic evaluations, and immunohistochemistry (IHC) confirmed their diagnoses. Kaplan-Meier survival curves and Cox regression analysis were applied to the SEER dataset to assess overall survival and treatment efficacy. P-values below 0.05 considered statistically significant. All four patients were diagnosed with prostate DLBCL via biopsy and confirmed by IHC, with extraprostatic involvement in three cases. Two patients achieved complete response, and one had partial response. In the SEER database, Kaplan-Meir analysis found that 59 patients had a 5-year survival rate of 59 months when it dropped in half, while multi-variable Cox regression highlighted age (HR 10.45, p < 0.001), surgery (HR 0.38, p = 0.0292), and radiation (HR 0.35, p = 0.0212) as the survival predictors. Although chemotherapy was administered in clinical practice, its impact was not statistically significant in our analysis. Prostate DLBCL is aggressive with diverse clinical presentations, making early detection and personalized treatment essential. Surgery and radiotherapy significantly improve patient outcomes, but the prognostic impact of chemotherapy, despite its widespread use, requires further validation through clinical trials.
本研究的目的是评估前列腺弥漫性大B细胞淋巴瘤（DLBCL）的临床表现、治疗策略和预后因素，旨在改善患者管理和治疗结果。我们对2014年至2024年在北京朝阳医院治疗的4例前列腺DLBCL病例进行了回顾性分析，并将这些结果与监测、流行病学和最终结果（SEER）数据集（2000 - 2021年）的数据相结合，以提供更广泛的背景信息。所有4例患者均接受了全面的诊断评估，免疫组织化学（IHC）证实了他们的诊断。将Kaplan-Meier生存曲线和Cox回归分析应用于SEER数据集，以评估总生存率和治疗效果。P值低于0.05被认为具有统计学意义。所有4例患者均通过活检诊断为前列腺DLBCL，并经IHC证实，其中3例有前列腺外受累。2例患者达到完全缓解，1例有部分缓解。在SEER数据库中，Kaplan-Meir分析发现，59例患者的5年生存率为59个月，生存率下降一半，而多变量Cox回归强调年龄（HR 10.45，p < 0.001）、手术（HR 0.38，p = 0.0292）和放疗（HR 0.35，p = 0.0212）为生存预测因素。虽然在临床实践中进行了化疗，但在我们的分析中其影响无统计学意义。前列腺DLBCL具有侵袭性，临床表现多样，因此早期检测和个性化治疗至关重要。手术和放疗显著改善了患者的治疗结果，但化疗的预后影响尽管广泛应用，仍需要通过临床试验进一步验证。
